Biosimilars company Shanghai Henlius Biotech Inc. (Shanghai, China) proposed on Friday to list on the Hong Kong stock exchange.
Shanghai Henlius’ lead compound is HLX01, a biosimilar of cancer and autoimmune drug MabThera rituximab from Roche (SIX:ROG; OTCQX:RHHBY). China’sNational Medical Products Administration (NMPA) is reviewing an NDA for the drug under Priority Review to treat non-Hodgkin lymphoma; Henlius expects a decision this year or early next.
According to its prospectus, the company’s pipeline includes over 25 biologics as well as immuno-oncology combination therapies.
Shanghai Henlius’ management team includes co-founders Scott Liu, who is president and CEO, and CSO Weidong Jiang. Prior to Henlius, Liu was director of the biologics QC department at Bristol-Myers Squibb Co. (NYSE:BMY) and the director of QAL/QC at Amgen Inc. (NASDAQ:AMGN). Jiang was an associate director at Catalyst Biosciences Inc. (NASDAQ:CBIO).
Shanghai Henlius’ substantial shareholders include Fosun International Ltd. (HKSE:656) and its Chairman Guangchang Guo as well as Fosun Pharmaceutical.
Underwriters for the offering include CICC, BofA Merrill Lynch, CMB International, Fosun Hani and Citi.
In September, Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) said its board approved a resolution to list Shanghai Henlius, a JV between Fosun and Henlius Biopharmaceuticals Co. Ltd. (Shanghai, China), in Hong Kong.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.